Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGH | Q92820 | 2/20 | 1.00 |
| ▸ | FOLH1 | Q04609 | 11/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.52 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.52 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374837 | 1.00 | GGH (1.00) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL5054338 | 0.89 | GGH (0.80) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL5054466 | 0.87 | GGH (0.77) | GGHFOLH1NAALAD2RIMKLA | |
| SCHEMBL5053238 | 0.86 | GGH (0.75) | GGHFOLH1 | |
| SCHEMBL5053167 | 0.86 | GGH (0.75) | GGHFOLH1 | |
| SCHEMBL5053165 | 0.86 | GGH (0.75) | GGHFOLH1 | |
| SCHEMBL5051207 | 0.84 | GGH (0.72) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL1615009 | 0.84 | GGH (0.72) | GGHFOLH1NAALAD2RIMKLAGRM3 | |
| SCHEMBL14243858 | 0.83 | GGH (0.71) | GGHFOLH1NAALAD2RIMKLA | |
| SCHEMBL2368891 | 0.83 | GGH (0.71) | GGHFOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY | 2025-02-27 | — | — | US | claimed |
| WO-2023154939-A2 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-17 | — | — | WO | claimed |
| US-11167049-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2021-11-09 | — | — | US | claimed |
| EP-3193914-B1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARM INC (US) | 2021-01-20 | — | — | EP | claimed |
| US-20200254120-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | US | claimed |
| US-10668174-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | claimed |
| US-20180207299-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | claimed |
| US-9956305-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | claimed |
| EP-3193914-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | Molecular Insight Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016040179-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20160067361-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-03-10 | — | — | US | claimed |
| US-6395718-B1 | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-05-28 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | COHERENT BIOPHARMA SUZHOU LTD (CN) | 2026-01-08 | — | — | US | disclosed |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-5863536-A | N-ACETYLATED ALPHA-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME INHIBITOR FOR THE TREATMENT OF GLUTAMATE ABNORMALITIES AND ASSOCIATED NERVOUS TISSUE ISCHEMIA IN A ANIMAL AND FOR TREATMENT OF PROSTATE DISEASE | GUILFORD PHARMACEUTICALS INC. (US) | 1999-01-26 | — | — | US | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207299-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | FOLH1, SHBG, KLK3 | GGH 140/4885FOLH1 1/4885NAALAD2 121/4885 |
| US-12496292-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | GGH 217/4885FOLH1 1/4885NAALAD2 49/4885 |
| US-10668174-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | FOLH1, SHBG, KLK3 | GGH 140/4885FOLH1 1/4885NAALAD2 121/4885 |
| US-20260007756-A1 | COMPOUND AND USE THEREOF | FOLH1, TRPV6, FOLR1 | GGH 2865/4885FOLH1 1/4885NAALAD2 1172/4885 |
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | DGKI, PGC, MPC2 | GGH 106/4885FOLH1 149/4885NAALAD2 572/4885 |
| US-20160067361-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | FOLH1, SHBG, KLK3 | GGH 140/4885FOLH1 1/4885NAALAD2 121/4885 |
| US-11167049-B2 | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer | FOLH1, SHBG, KLK3 | GGH 140/4885FOLH1 1/4885NAALAD2 121/4885 |
| US-20200254120-A1 | ORGAN PROTECTION IN PSMA-TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | FOLH1, SHBG, KLK3 | GGH 140/4885FOLH1 1/4885NAALAD2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.